Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Medtronic announces enrollment in ADAPT-PD trial » 08:36
01/14/21
01/14
08:36
01/14/21
08:36
MDT

Medtronic

$118.75 /

+1.345 (+1.15%)

Medtronic announced the…

Medtronic announced the first enrollment in ADAPT-PD, its trial evaluating the safety and efficacy of adaptive deep brain stimulation in patients with Parkinson's Disease. Adaptive deep brain stimulation is an investigational feature of the Percept(TM) PC device that could be enabled if approved. The investigational feature used in this study allows for automated adjustment of brain stimulation to provide therapy to manage symptoms of Parkinson's disease based on a patient's clinical state.

ShowHide Related Items >><<
MDT Medtronic
$118.75 /

+1.345 (+1.15%)

MDT Medtronic
$118.75 /

+1.345 (+1.15%)

01/13/21 Piper Sandler
MCIT finalized rule 'important win' for medical technology, says Piper Sandler
01/11/21 Piper Sandler
Medtronic updates thoughts on Q3, products, says Piper Sandler
01/07/21 Morgan Stanley
Axonics price target raised to $58 from $53 at Morgan Stanley
12/22/20 JPMorgan
JPMorgan ups Medtronic target to $130, names a top pick for 2021
MDT Medtronic
$118.75 /

+1.345 (+1.15%)

MDT Medtronic
$118.75 /

+1.345 (+1.15%)

MDT Medtronic
$118.75 /

+1.345 (+1.15%)

MDT Medtronic
$118.75 /

+1.345 (+1.15%)

Wednesday
Recommendations
MCIT finalized rule 'important win' for medical technology, says Piper Sandler » 04:58
01/13/21
01/13
04:58
01/13/21
04:58
BSX

Boston Scientific

$35.32 /

-1.12 (-3.07%)

, EW

Edwards Lifesciences

$87.84 /

-1.54 (-1.72%)

, MASI

Masimo

$278.15 /

-2.07 (-0.74%)

, MDT

Medtronic

$117.41 /

-1.005 (-0.85%)

, MMSI

Merit Medical

$55.52 /

-0.92 (-1.63%)

, STIM

Neuronetics

$11.69 /

-0.36 (-2.99%)

, SWAV

ShockWave Medical

$121.83 /

+4.6 (+3.92%)

Centers for Medicare and…

Centers for Medicare and Medicaid Services yesterday announced that the Medicare Coverage of Innovative Technology proposal announced in August 2020) has been made into a final rule, Piper Sandler analyst Matt O'Brien tells investors in a research note. Under this new rule, medical devices with FDA Breakthrough Device Designation will be eligible for up to four years of national Medicare coverage simultaneously with FDA approval, says the analyst. Additionally, Breakthrough Devices that were approved within the past two calendar years will also be eligible for coverage under this rule, adds the analyst. O'Brien calls the news an "important win" for the medical technology space and believes Boston Scientific (BSX), Edwards Lifesciences (EW), Masimo (MASI), Medtronic (MDT), Merit Medical (MMSI), Neuronetics (STIM) and hockWave Medical (SWAV) stand to benefit.

ShowHide Related Items >><<
SWAV ShockWave Medical
$121.83 /

+4.6 (+3.92%)

STIM Neuronetics
$11.69 /

-0.36 (-2.99%)

MMSI Merit Medical
$55.52 /

-0.92 (-1.63%)

MDT Medtronic
$117.41 /

-1.005 (-0.85%)

MASI Masimo
$278.15 /

-2.07 (-0.74%)

EW Edwards Lifesciences
$87.84 /

-1.54 (-1.72%)

BSX Boston Scientific
$35.32 /

-1.12 (-3.07%)

BSX Boston Scientific
$35.32 /

-1.12 (-3.07%)

01/12/21 Piper Sandler
Piper says Boston Scientific pullback an opportunity to build positions
12/23/20 Piper Sandler
Boston Scientific a name to own at current share levels, says Piper Sandler
12/15/20 Goldman Sachs
Boston Scientific downgraded to Buy from Conviction Buy at Goldman Sachs
12/15/20 Goldman Sachs
Medtronic upgraded to Neutral from Sell at Goldman Sachs
EW Edwards Lifesciences
$87.84 /

-1.54 (-1.72%)

12/16/20 Citi
Edwards Lifesciences downgraded to Neutral from Buy at Citi
12/11/20 Canaccord
Edwards Lifesciences price target raised to $94 from $89 at Canaccord
12/11/20 Piper Sandler
Edwards Lifesciences price target raised to $98 from $93 at Piper Sandler
12/07/20 Credit Suisse
Edwards Lifesciences price target raised to $111 from $97 at Credit Suisse
MASI Masimo
$278.15 /

-2.07 (-0.74%)

11/02/20 Piper Sandler
Masimo acquisition brings 'solid opportunity,' says Piper Sandler
10/28/20 Piper Sandler
Masimo price target raised to $280 from $250 at Piper Sandler
10/06/20 Piper Sandler
Better than expected sensor utilization drove Masimo upside, says Piper Sandler
09/01/20 Baird
Masimo initiated with an Outperform at Baird
MDT Medtronic
$117.41 /

-1.005 (-0.85%)

01/11/21 Piper Sandler
Medtronic updates thoughts on Q3, products, says Piper Sandler
01/07/21 Morgan Stanley
Axonics price target raised to $58 from $53 at Morgan Stanley
12/22/20 JPMorgan
JPMorgan ups Medtronic target to $130, names a top pick for 2021
12/15/20 Morgan Stanley
Morgan Stanley upgrades Medtronic to Overweight on core improvements, pipeline
MMSI Merit Medical
$55.52 /

-0.92 (-1.63%)

01/05/21 Needham
Merit Medical upgraded to Buy from Hold at Needham
01/05/21 Needham
Merit Medical upgraded to Buy from Hold at Needham
11/11/20 Wells Fargo
Merit Medical price target raised to $58 from $51 at Wells Fargo
11/11/20 Oppenheimer
Merit Medical price target raised to $60 from $55 at Oppenheimer
STIM Neuronetics
$11.69 /

-0.36 (-2.99%)

01/12/21 Piper Sandler
Neuronetics price target raised to $20 from $9 at Piper Sandler
01/08/21 JMP Securities
Neuronetics price target raised to $15 from $10 at JMP Securities
12/07/20 BTIG
Neuronetics price target raised to $14 from $10 at BTIG
11/23/20 Piper Sandler
Neuronetics price target raised to $9 from $7 at Piper Sandler
SWAV ShockWave Medical
$121.83 /

+4.6 (+3.92%)

01/12/21 Wells Fargo
ShockWave Medical price target raised to $134 from $95 at Wells Fargo
12/03/20 Piper Sandler
Piper boosts ShockWave Medical target to $96, likes setup into 2021
12/02/20 Oppenheimer
Oppenheimer stays at Perform on ShockWave, highlights paper on IVL-induced VFib
12/01/20 BofA
ShockWave Medical downgraded to Neutral from Buy at BofA
SWAV ShockWave Medical
$121.83 /

+4.6 (+3.92%)

STIM Neuronetics
$11.69 /

-0.36 (-2.99%)

MMSI Merit Medical
$55.52 /

-0.92 (-1.63%)

MDT Medtronic
$117.41 /

-1.005 (-0.85%)

MASI Masimo
$278.15 /

-2.07 (-0.74%)

EW Edwards Lifesciences
$87.84 /

-1.54 (-1.72%)

BSX Boston Scientific
$35.32 /

-1.12 (-3.07%)

  • 17
    Jun
  • 22
    May
MDT Medtronic
$117.41 /

-1.005 (-0.85%)

BSX Boston Scientific
$35.32 /

-1.12 (-3.07%)

STIM Neuronetics
$11.69 /

-0.36 (-2.99%)

MDT Medtronic
$117.41 /

-1.005 (-0.85%)

MASI Masimo
$278.15 /

-2.07 (-0.74%)

EW Edwards Lifesciences
$87.84 /

-1.54 (-1.72%)

BSX Boston Scientific
$35.32 /

-1.12 (-3.07%)

STIM Neuronetics
$11.69 /

-0.36 (-2.99%)

MDT Medtronic
$117.41 /

-1.005 (-0.85%)

EW Edwards Lifesciences
$87.84 /

-1.54 (-1.72%)

BSX Boston Scientific
$35.32 /

-1.12 (-3.07%)

Monday
Hot Stocks
Medtronic CEO: We're putting more money into R&D » 18:24
01/11/21
01/11
18:24
01/11/21
18:24
MDT

Medtronic

$118.47 /

-1.29 (-1.08%)

In an interview on…

In an interview on CNBC's Mad Money, Geoff Martha said the use of data will change healthcare. Therapies are improving and becoming more personalized due to advances in technology, he noted. Medtronic is putting more money into R&D and using its balance sheet more than in the past, Martha added. He said the company is "committed" to the dividend and to a double digit return.

ShowHide Related Items >><<
MDT Medtronic
$118.47 /

-1.29 (-1.08%)

MDT Medtronic
$118.47 /

-1.29 (-1.08%)

01/11/21 Piper Sandler
Medtronic updates thoughts on Q3, products, says Piper Sandler
01/07/21 Morgan Stanley
Axonics price target raised to $58 from $53 at Morgan Stanley
12/22/20 JPMorgan
JPMorgan ups Medtronic target to $130, names a top pick for 2021
12/15/20 Morgan Stanley
Morgan Stanley upgrades Medtronic to Overweight on core improvements, pipeline
MDT Medtronic
$118.47 /

-1.29 (-1.08%)

MDT Medtronic
$118.47 /

-1.29 (-1.08%)

MDT Medtronic
$118.47 /

-1.29 (-1.08%)

MDT Medtronic
$118.47 /

-1.29 (-1.08%)

Recommendations
Medtronic updates thoughts on Q3, products, says Piper Sandler » 12:58
01/11/21
01/11
12:58
01/11/21
12:58
MDT

Medtronic

$118.46 /

-1.3 (-1.09%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien made no change to his Overweight rating on Medtronic shares and continues to be "positively inclined" after the company provided updated thoughts on its Q3 at a conference and provided some updates on its pipeline products. O'Brien sees a number of potential growth drivers in the coming years, a strong balance sheet, and a reasonable valuation relative to other diversified names, and noted that the company disclosed that it is developing its own ECAPs closed loop spinal cord stimulation platform which it expects to submit for FDA approval later this year.

ShowHide Related Items >><<
MDT Medtronic
$118.46 /

-1.3 (-1.09%)

MDT Medtronic
$118.46 /

-1.3 (-1.09%)

01/07/21 Morgan Stanley
Axonics price target raised to $58 from $53 at Morgan Stanley
12/22/20 JPMorgan
JPMorgan ups Medtronic target to $130, names a top pick for 2021
12/15/20 Morgan Stanley
Morgan Stanley upgrades Medtronic to Overweight on core improvements, pipeline
12/15/20 Goldman Sachs
Medtronic upgraded to Neutral from Sell at Goldman Sachs
MDT Medtronic
$118.46 /

-1.3 (-1.09%)

MDT Medtronic
$118.46 /

-1.3 (-1.09%)

MDT Medtronic
$118.46 /

-1.3 (-1.09%)

MDT Medtronic
$118.46 /

-1.3 (-1.09%)

Hot Stocks
Medtronic Canada receives expanded indication from Health Canada for Evolut » 07:55
01/11/21
01/11
07:55
01/11/21
07:55
MDT

Medtronic

$119.74 /

+1.045 (+0.88%)

Medtronic Canada ULC, a…

Medtronic Canada ULC, a subsidiary of Medtronic, has received a new expanded indication from Health Canada for its Evolut Transcatheter Aortic Valve Implantation system. Medtronic's TAVI platform is currently the only system licensed for both bicuspid aortic valves as well as all surgical risk categories in Canada. Evolut is now indicated in Canada for severe aortic stenosis patients across all risk categories. With this new indication, over 10,500 people in Canada are potential candidates for this minimally invasive alternative to open-heart surgical valve replacement each year. The expanded indication also allows patients with bicuspid aortic valves at extreme, high and intermediate risk of surgical mortality to also receive the procedure.

ShowHide Related Items >><<
MDT Medtronic
$119.74 /

+1.045 (+0.88%)

MDT Medtronic
$119.74 /

+1.045 (+0.88%)

01/07/21 Morgan Stanley
Axonics price target raised to $58 from $53 at Morgan Stanley
12/22/20 JPMorgan
JPMorgan ups Medtronic target to $130, names a top pick for 2021
12/15/20 Morgan Stanley
Morgan Stanley upgrades Medtronic to Overweight on core improvements, pipeline
12/15/20 Goldman Sachs
Medtronic upgraded to Neutral from Sell at Goldman Sachs
MDT Medtronic
$119.74 /

+1.045 (+0.88%)

MDT Medtronic
$119.74 /

+1.045 (+0.88%)

MDT Medtronic
$119.74 /

+1.045 (+0.88%)

MDT Medtronic
$119.74 /

+1.045 (+0.88%)

Over a week ago
Recommendations
Axonics price target raised to $58 from $53 at Morgan Stanley » 08:42
01/07/21
01/07
08:42
01/07/21
08:42
AXNX

Axonics

$51.56 /

+1.14 (+2.26%)

, MDT

Medtronic

$118.83 /

+1.95 (+1.67%)

Morgan Stanley analyst…

Morgan Stanley analyst David Lewis raised the firm's price target on Axonics (AXNX) to $58 from $53 and keeps an Overweight rating on the shares after surveying 54 high-volume physicians who drive about 12% of total U.S. SNM implant volumes. While Medtronic's (MDT) Interstim Micro launch appears to be arresting some of Axonics' share gain momentum, these physicians still expect their share of Axonics' rSNM procedures to grow over the next one to two years, Lewis tells investors.

ShowHide Related Items >><<
MDT Medtronic
$118.83 /

+1.95 (+1.67%)

AXNX Axonics
$51.56 /

+1.14 (+2.26%)

AXNX Axonics
$51.56 /

+1.14 (+2.26%)

12/01/20 BofA
ShockWave Medical downgraded to Neutral from Buy at BofA
11/24/20 Piper Sandler
Piper says accelerating SNM market an underappreciated positive for Axonics
11/05/20 Truist
Axonics price target raised to $58 from $50 at Truist
11/05/20 Wells Fargo
Axonics price target raised to $57 from $51 at Wells Fargo
MDT Medtronic
$118.83 /

+1.95 (+1.67%)

12/22/20 JPMorgan
JPMorgan ups Medtronic target to $130, names a top pick for 2021
12/15/20 Morgan Stanley
Morgan Stanley upgrades Medtronic to Overweight on core improvements, pipeline
12/15/20 Goldman Sachs
Medtronic upgraded to Neutral from Sell at Goldman Sachs
12/15/20 Morgan Stanley
Medtronic upgraded to Overweight from Equal Weight at Morgan Stanley
MDT Medtronic
$118.83 /

+1.95 (+1.67%)

AXNX Axonics
$51.56 /

+1.14 (+2.26%)

  • 08
    May
MDT Medtronic
$118.83 /

+1.95 (+1.67%)

MDT Medtronic
$118.83 /

+1.95 (+1.67%)

AXNX Axonics
$51.56 /

+1.14 (+2.26%)

MDT Medtronic
$118.83 /

+1.95 (+1.67%)

Recommendations
JPMorgan ups Medtronic target to $130, names a top pick for 2021 » 09:25
12/22/20
12/22
09:25
12/22/20
09:25
MDT

Medtronic

$114.45 /

-0.97 (-0.84%)

JPMorgan analyst Robbie…

JPMorgan analyst Robbie Marcus raised the firm's price target on Medtronic to $130 from $122 and keeps an Overweight rating on the shares. The analyst also named Medtronic a top large cap pick for 2021. With a new CEO, new operating model, and a "robust" product pipeline, the pieces are in place for Medtronic to deliver a strong 2021, Marcus tells investors in a research note. The analyst sees 2021 as a "significant year for Medtronic as the turnaround story continues to play out."

ShowHide Related Items >><<
MDT Medtronic
$114.45 /

-0.97 (-0.84%)

MDT Medtronic
$114.45 /

-0.97 (-0.84%)

12/15/20 Morgan Stanley
Morgan Stanley upgrades Medtronic to Overweight on core improvements, pipeline
12/15/20 Goldman Sachs
Medtronic upgraded to Neutral from Sell at Goldman Sachs
12/15/20 Morgan Stanley
Medtronic upgraded to Overweight from Equal Weight at Morgan Stanley
12/14/20 Piper Sandler
Resignation of Medtronic President of Cardiovascular a surprise, says Piper
MDT Medtronic
$114.45 /

-0.97 (-0.84%)

MDT Medtronic
$114.45 /

-0.97 (-0.84%)

MDT Medtronic
$114.45 /

-0.97 (-0.84%)

MDT Medtronic
$114.45 /

-0.97 (-0.84%)

Hot Stocks
Medtronic's White sells nearly 11,000 common shares » 17:10
12/21/20
12/21
17:10
12/21/20
17:10
MDT

Medtronic

$114.45 /

-0.97 (-0.84%)

In a regulatory filing,…

In a regulatory filing, Medtronic EVP and President, Medical Surgical, Robert John White disclosed the sale of 10,930 ordinary shares of the company on December 18 at a price of $115.46 per share.

ShowHide Related Items >><<
MDT Medtronic
$114.45 /

-0.97 (-0.84%)

MDT Medtronic
$114.45 /

-0.97 (-0.84%)

12/15/20 Morgan Stanley
Morgan Stanley upgrades Medtronic to Overweight on core improvements, pipeline
12/15/20 Goldman Sachs
Medtronic upgraded to Neutral from Sell at Goldman Sachs
12/15/20 Morgan Stanley
Medtronic upgraded to Overweight from Equal Weight at Morgan Stanley
12/14/20 Piper Sandler
Resignation of Medtronic President of Cardiovascular a surprise, says Piper
MDT Medtronic
$114.45 /

-0.97 (-0.84%)

MDT Medtronic
$114.45 /

-0.97 (-0.84%)

MDT Medtronic
$114.45 /

-0.97 (-0.84%)

MDT Medtronic
$114.45 /

-0.97 (-0.84%)

Hot Stocks
Medtronic announces FDA approval of navigated interbody, Midas Rex drills » 08:03
12/16/20
12/16
08:03
12/16/20
08:03
MDT

Medtronic

$114.84 /

+2.855 (+2.55%)

Medtronic announced that…

Medtronic announced that the U.S. FDA has cleared the use of navigated interbody and Midas Rex high speed drills with the Mazor Robotic Guidance System earlier than originally anticipated. The Mazor platform now provides surgeons with unprecedented procedural integration by seamlessly combining the power of Midas Rex drills with the market leading visibility and navigation from the StealthStation software. The solution delivers the confidence of access and interbody navigation and predictability of planning, along with the precision of robotic technology that surgeons expect from the Mazor Robotic Guidance System and the exclusive Medtronic robotics portfolio.

ShowHide Related Items >><<
MDT Medtronic
$114.84 /

+2.855 (+2.55%)

MDT Medtronic
$114.84 /

+2.855 (+2.55%)

12/15/20 Morgan Stanley
Morgan Stanley upgrades Medtronic to Overweight on core improvements, pipeline
12/15/20 Goldman Sachs
Medtronic upgraded to Neutral from Sell at Goldman Sachs
12/15/20 Morgan Stanley
Medtronic upgraded to Overweight from Equal Weight at Morgan Stanley
12/14/20 Piper Sandler
Resignation of Medtronic President of Cardiovascular a surprise, says Piper
MDT Medtronic
$114.84 /

+2.855 (+2.55%)

MDT Medtronic
$114.84 /

+2.855 (+2.55%)

MDT Medtronic
$114.84 /

+2.855 (+2.55%)

MDT Medtronic
$114.84 /

+2.855 (+2.55%)

Conference/Events
Food & Drug Law Institute to hold a virtual conference » 04:55
12/16/20
12/16
04:55
12/16/20
04:55
BDX

Becton Dickinson

$244.15 /

+3.8 (+1.58%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, EXPO

Exponent

$87.74 /

+1.61 (+1.87%)

, LLY

Eli Lilly

$167.46 /

+9.5 (+6.01%)

, MDT

Medtronic

$114.84 /

+2.855 (+2.55%)

, PFE

Pfizer

$38.72 /

-0.51 (-1.30%)

, ZGNX

Zogenix

$21.01 /

-0.13 (-0.61%)

Enforcement, Litigation…

Enforcement, Litigation & Compliance Conference will be held on December 15-16. Webcast Link

ShowHide Related Items >><<
ZGNX Zogenix
$21.01 /

-0.13 (-0.61%)

PFE Pfizer
$38.72 /

-0.51 (-1.30%)

MDT Medtronic
$114.84 /

+2.855 (+2.55%)

LLY Eli Lilly
$167.46 /

+9.5 (+6.01%)

BDX Becton Dickinson
$244.15 /

+3.8 (+1.58%)

BDX Becton Dickinson
$244.15 /

+3.8 (+1.58%)

12/15/20
Fly Intel: Top five analyst downgrades
12/15/20
Fly Intel: Top five analyst upgrades
12/15/20 Morgan Stanley
Morgan Stanley upgrades 'self help story in disguise' Becton Dickinson
12/15/20 Wells Fargo
Wells Fargo says Buy Inari Medical, Sell NuVasive in MedTech ratings shake-up
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

EXPO Exponent
$87.74 /

+1.61 (+1.87%)

05/13/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
04/09/20 Sidoti
Exponent downgraded to Neutral from Buy at Sidoti
03/19/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
03/19/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
LLY Eli Lilly
$167.46 /

+9.5 (+6.01%)

12/15/20 Piper Sandler
Prevail Therapeutics downgraded to Neutral from Overweight at Piper Sandler
12/10/20 Wolfe Research
Eli Lilly upgraded to Outperform from Peer Perform at Wolfe Research
12/10/20 Wolfe Research
Eli Lilly upgraded to Outperform from Peer Perform at Wolfe Research
12/04/20 JPMorgan
Eli Lilly best positioned growth story in space, says JPMorgan
MDT Medtronic
$114.84 /

+2.855 (+2.55%)

12/15/20 Morgan Stanley
Morgan Stanley upgrades Medtronic to Overweight on core improvements, pipeline
12/15/20 Goldman Sachs
Medtronic upgraded to Neutral from Sell at Goldman Sachs
12/15/20 Morgan Stanley
Medtronic upgraded to Overweight from Equal Weight at Morgan Stanley
12/14/20 Piper Sandler
Resignation of Medtronic President of Cardiovascular a surprise, says Piper
PFE Pfizer
$38.72 /

-0.51 (-1.30%)

12/15/20 Jefferies
Jefferies starts Maravai at Buy, says 'more than just a COVID vaccine play'
12/14/20 Jefferies
Novavax initiated with a Buy at Jefferies
12/14/20 Citi
Arcturus Therapeutics price target raised to $133 from $62 at Citi
12/08/20 Roth Capital
Turning Point Therapeutics price target raised to $140 from $133 at Roth Capital
ZGNX Zogenix
$21.01 /

-0.13 (-0.61%)

12/04/20 Mizuho
Zogenix collaboration step in right direction, says Mizuho
08/24/20 Raymond James
Zogenix initiated with a Market Perform at Raymond James
07/15/20 Stifel
Physician survey suggests Zogenix shares undervalued, says Stifel
06/29/20 Mizuho
Zogenix price target lowered to $55 from $64 at Mizuho
ZGNX Zogenix
$21.01 /

-0.13 (-0.61%)

PFE Pfizer
$38.72 /

-0.51 (-1.30%)

MDT Medtronic
$114.84 /

+2.855 (+2.55%)

LLY Eli Lilly
$167.46 /

+9.5 (+6.01%)

EXPO Exponent
$87.74 /

+1.61 (+1.87%)

BDX Becton Dickinson
$244.15 /

+3.8 (+1.58%)

  • 21
    May
  • 04
    Mar
ZGNX Zogenix
$21.01 /

-0.13 (-0.61%)

PFE Pfizer
$38.72 /

-0.51 (-1.30%)

MDT Medtronic
$114.84 /

+2.855 (+2.55%)

LLY Eli Lilly
$167.46 /

+9.5 (+6.01%)

BDX Becton Dickinson
$244.15 /

+3.8 (+1.58%)

ZGNX Zogenix
$21.01 /

-0.13 (-0.61%)

PFE Pfizer
$38.72 /

-0.51 (-1.30%)

MDT Medtronic
$114.84 /

+2.855 (+2.55%)

LLY Eli Lilly
$167.46 /

+9.5 (+6.01%)

BDX Becton Dickinson
$244.15 /

+3.8 (+1.58%)

ZGNX Zogenix
$21.01 /

-0.13 (-0.61%)

PFE Pfizer
$38.72 /

-0.51 (-1.30%)

MDT Medtronic
$114.84 /

+2.855 (+2.55%)

LLY Eli Lilly
$167.46 /

+9.5 (+6.01%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.